Fundraising FoxMikrobiomik
1 known investors
Find your way into Mikrobiomik
Sign up to see every warm intro you have to Mikrobiomik
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mikrobiomik team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MikrobioMik develops full-spectrum gut microbiota therapies, led by EUTEGRA (MBK-01), a regulatory-authorized treatment for recurrent Clostridioides difficile infection. The company is building a clinical pipeline applying microbial restoration to conditions with limited treatment options, including recurrent acute diverticulitis and decompensated liver cirrhosis.
Investors · 1
Frequently asked questions
- What does Mikrobiomik do?
- MikrobioMik develops full-spectrum gut microbiota therapies, led by EUTEGRA (MBK-01), a regulatory-authorized treatment for recurrent Clostridioides difficile infection. The company is building a clinical pipeline applying microbial restoration to conditions with limited treatment options, including recurrent acute diverticulitis and decompensated liver cirrhosis.
- Who are Mikrobiomik's investors?
- Mikrobiomik's investors include Seed Capital Bizkaia SA.